博来霉素注射联合环钻切除与X线放疗治疗中大型瘢痕疙瘩
该回顾性研究纳入69例患者共137处瘢痕疙瘩,比较博来霉素与曲安奈德联合环钻切除及术后4次浅层X线放疗(SXRT)的疗效与安全性。12个月时两组VSS均显著改善,博来霉素组VSS降幅更大(68% vs 58.82%,p<0.05),应答率更高(82.5% vs 60.0%),满意度更高且不良事件更少;复发率两组差异无统计学意义(1.16% vs 3.92%,P>0.05)。
要点
- 博来霉素联合环钻切除与SXRT治疗中大型瘢痕疙瘩VSS降幅达68%,优于曲安奈德组58.82%。
- 博来霉素组应答率82.5%、满意度更高,不良事件少于曲安奈德组。
- 两组复发率分别为1.16%与3.92%,差异无统计学意义(P>0.05)。
核心结论
- 博来霉素联合环钻切除与SXRT(B-P-X)治疗中大型瘢痕疙瘩临床疗效好、复发率低、不良反应少。
- 12个月时博来霉素组VSS降幅、应答率与满意度均优于曲安奈德组,不良事件更少。
- 两组复发率差异无统计学意义(1.16% vs 3.92%,P>0.05)。
研究设计与样本
- 回顾性研究,纳入南方医科大学皮肤病医院69例患者共137处瘢痕疙瘩。
- 所有患者行环钻切除并术中病灶内注射博来霉素或曲安奈德,术后接受4次SXRT。
- 基线及治疗后12个月用VSS评估,并分析复发率、满意度与不良事件,SPSS 26.0分析(P<0.05)。
主要发现
- 12个月时两组VSS均显著改善(P<0.05)。
- 博来霉素组VSS降幅大于曲安奈德组(68% vs 58.82%,p<0.05)。
- 博来霉素组应答率更高(82.5% vs 60.0%),满意度更高(P<0.05)。
- 博来霉素组不良事件更少(P<0.05):溃疡2例、色素沉着5例。
- 曲安奈德组不良事件包括溃疡1例、毛细血管扩张5例、色素沉着4例、色素减退6例、病灶内钙化沉积4例。
关键数值与推荐
- VSS评估时间点为基线及治疗后12个月。
- 博来霉素组VSS降幅68%,曲安奈德组58.82%(p<0.05)。
- 应答率:博来霉素组82.5%,曲安奈德组60.0%。
- 复发率:博来霉素组1.16%,曲安奈德组3.92%(P>0.05)。
- 证据等级:治疗性,Ⅳ级。
临床怎么用
- 对中大型瘢痕疙瘩可考虑环钻切除联合术中博来霉素注射及术后SXRT的综合方案。
- 选择博来霉素方案时需权衡其较少不良事件与曲安奈德组色素改变、钙化等风险。
- 术后需随访12个月以上评估VSS与复发,因两组复发率差异未达统计学意义。
局限性
- 为单中心回顾性研究,证据等级Ⅳ级。
- 样本量有限(69例患者、137处病灶),结论需前瞻性研究验证。
- 原文未报告随访超过12个月的数据及具体随机化或盲法信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Keloids are an inflammatory skin disorder caused by dysregulated wound healing after cutaneous injury or irritation,often accompanied by pruritus and pain. Therapeutic challenges include high recurrence rates and treatment resistance, particularly in medium-to-large keloids. Current guidelines recommend combination therapies, yet standardized protocols remain elusive. This study compares the efficacy and safety of bleomycin versus triamcinolone combined with punch excision and SXRT(superficial X-ray therapy). METHODS: A retrospective analysis of 69 patients (137 keloid lesions) treated at the Dermatology Hospital of Southern Medical University was conducted. All subjects underwent punch excision with intraoperative intralesional injection (bleomycin or triamcinolone) followed by 4 sessions of postoperative SXRT. Outcomes were assessed using VSS at baseline and 12 months post-treatment, alongside recurrence rates, satisfaction, and adverse events. Data were analyzed using SPSS 26.0 (P < 0.05). RESULTS: At 12 months, both groups showed significant VSS improvement (P < 0.05). The bleomycin group showed greater VSS reduction than the triamcinolone group (68% vs 58.82%, p<0.05).The bleomycin group exhibited higher response rates (82.5% vs. 60.0%) and satisfaction (P < 0.05), with fewer adverse events (P < 0.05): ulceration (2 cases), hyperpigmentation (5 cases).While in the triamcinolone group, adverse events included ulceration (1 case), telangiectasia (5 cases), hyperpigmentation (4 cases), and hypopigmentation (6 cases),Intralesional calcification deposition (4 cases). Recurrence rates were 1.16% (bleomycin) and 3.92% (triamcinolone) (P > 0.05). CONCLUSIONS: B-P-X therapy is a novel combined treatment modality incorporating punch excision, bleomycin injection, and SXRT for medium-to-large keloids, demonstrating excellent clinical efficacy, low recurrence rates, and minimal adverse effects. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, Ⅳ.
引用
- Liu X, Fu Z, Zheng W, et al. Bleomycin Injection Combined with Punch Excision and X-ray Radiotherapy for Treating Medium to Large Keloids: A Retrospective Study. Plast Reconstr Surg. 2026. PMID: 41563738. doi:10.1097/PRS.0000000000012809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。